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Selenium compounds have been implicated as anticancer 
agents; however, the mechanism of their inhibitory action 
against cancer development has not been extensively in-
vestigated. A constitutive activation of the Wnt/β-catenin 
pathway is a central event in colorectal carcinogenesis. 
In this pathway, excessive cell proliferation is initiated 
by generation of β-catenin followed by overexpression 
of proto-oncogenes, such as c-Myc. It is believed that 
under physiological conditions the level of c-Myc is effi-
ciently controlled by accessibility of the β-catenin protein 
through the process of phosphorylation by glycogen syn-
thase kinase 3β (GSK-3β). Here, we determined whether 
selenomethionine (SeMet) can inhibit cell growth and af-
fect the Wnt/β-catenin pathway in the HT-29 human colo-
rectal cancer cells in vitro. The effective cytotoxic doses of 
SeMet have been selected after 48 h of incubation of this 
compound with colorectal cancer HT-29 cell line. MTT as-
say was used to assess cell viability and the protein and 
mRNA levels of β-catenin and c-Myc were determined by 
Western blotting and qPCR, respectively. SeMet potently 
inhibited growth of HT-29 cells, significantly decreased 
level of the β-catenin protein and mRNA concentration, 
down-regulated the c-Myc gene expression and up-regu-
lated the pro-apoptotic Bax protein level. Moreover, Se-
Met increased the level of GSK-3β phosphorylated at ser-
ine 9 (S9) and significantly increased the level of β-catenin 
phosphorylated at S33 and S37. We conclude that SeMet 
suppresses growth of HT-29 colorectal cancer cells by a 
mechanism linked to the Wnt/β-catenin pathway, how-
ever, degradation of β-catenin may occur independently 
of GSK-3β catalytic activity and its phosphorylation status.
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INTRODUCTION
Over the last few decades convincing evidence has 
been accumulated indicating that selenium compounds 
are good candidates for cancer treatment and chemo-
prevention. However, despite promising results, there 
is still little information available on the molecular ge-
netics background underlying anti-tumorigenic effects 
of these compounds. The cellular responses induced by 
selenium in experimental models are very diverse and 
may depend on different forms and doses of this micro-
element (Brozmanova et al., 2010). Major dietary seleno-
compounds are the following amino acids: selenomethio-
nine (SeMet), selenocysteine and Se-methylselenocysteine 
(Combs et al., 1998; Rayman, 2000; Brozmanova et al., 
2010; Korbut et al., 2012). For instance, SeMet has been 
shown in numerous cancer models to inhibit neoplastic 
cell growth (Nelson et al., 2005; Goulet et al., 2007). It 
has been also reported that SeMet is less toxic than oth-
er selenium compounds, making it the selenium deriva-
tive form of choice for human interventional trials (Red-
man et al., 1997). Moreover, unlike selenite and seleno-
cysteine, SeMet failed to exhibit glutathione peroxidase 
(GPx) activity known to protect the cells from oxidative 
damage. This clearly suggests that cytotoxic activity of 
SeMet involves a different mechanism, in part unrelated 
to antioxidative activity of this compound (Beutler et al., 
1975). This was also confirmed by meta-analysis in an 
animal model which revealed that selenium-enriched diet 
showed greater potency in increasing GPx activity than 
SeMet (Bermingham et al., 2014).
One of the most attractive targets for anti-cancer ther-
apy seems to be the Wnt/β-catenin pathway. An abnor-
mal activation of this signalling pathway has already been 
described in a wide variety of human cancers (Kikuchi, 
2003; Anastas et al., 2013; Han et al., 2013). Interestingly, 
over 90% of colorectal cancers have demonstrated ab-
normal regulation of the Wnt/β-catenin signalling (Fevr 
et al., 2007; Polakis, 2012).
The level of β-catenin, the central signalling pro-
tein of the Wnt/β-catenin pathway, is regulated by the 
activity of a destruction complex that is composed of 
the Axin scaffolding protein, the adenomatosis polypo-
sis coli protein (APC), casein kinase 1 (CK1), and the 
glycogen synthetase kinase 3β (GSK-3β). In the absence 
of Wnt signalling, GSK-3β sequentially phosphorylates 
β-catenin at S33 and S37, resulting in β-catenin recogni-
tion by β-TrCP, an E3 ubiquitin ligase subunit, and sub-
sequent β-catenin ubiquitination and proteasomal degra-
dation (He et al., 2004) (Fig. 1, left panel). In turn, in 
the presence of Wnt signalling, β-catenin accumulates in 
the cytoplasm and then it can translocate into the nu-
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cleus. The nuclear β-catenin interacts with transcription 
factors – TCF/LEF, enhancing expression of c-Myc 
and other genes. The activity of GSK-3β is silenced by 
phosphorylation at S9. This phosphorylation induces a 
pseudo-substrate conformation in the substrate docking 
motifs of GSK-3β that acts as a competitive inhibitor 
for true substrates (Doble, 2003; McCubrey et al., 2014). 
These events play a pivotal role in the control of cell 
proliferation, differentiation and cell apoptosis (Clevers, 
2006; Pecina-Slaus, 2010; Miller et al., 2012) (Fig. 1, right 
panel). Moreover, elevated β-catenin mRNA levels which 
correlate with constitutively high amounts or nuclear 
localization of β-catenin, were found in several tumors, 
including colorectal carcinomas (Bandapalli et al., 2009).
The link between the Wnt signalling and apopto-
sis has become increasingly established in the literature 
(Pecina-Slaus, 2010). The Bcl-2 and Bax family of pro-
teins play an important role in the regulation of the 
programmed cell death known as apoptosis. While Bcl-
2 promotes cell survival, the structurally similar Bax in-
duces programmed cell death by permeabilization of the 
outer mitochondrial membrane. Impairment of apoptosis 
is generally accepted as the central event in the mecha-
nism of cancer development and seems to be responsi-
ble for tumour resistance to cytotoxic therapeutics (Ad-
ams et al., 2007).
In view of the above, we designed our study to deter-
mine the effect of SeMet on colorectal cancer cell pro-
liferation, and Bax-mediated apoptosis, and we examined 
whether Wnt/β-catenin is involved in these effects of 
SeMet on cancer cells in vitro.
MATERIALS AND METHODS
 Cell lines. Human epithelial colorectal adenocarci-
noma cell line (HT-29) was purchased from European 
Collection of Animal Cell Cultures (ECACC) (Salisbury, 
UK). HT-29 cell line was maintained in RPMI 1640 me-
dium (with L-glutamine and sodium bicarbonate) from 
Sigma Aldrich (St. Louis, MO, USA) supplemented with 
10% (v/v) foetal bovine serum (FBS) (Sigma Aldrich, St. 
Louis, MO, USA). Human keratinocyte cell line (HaCaT) 
was purchased from CLS Cell Lines Service GmbH 
(Heidelberg, Germany). HaCaT cell line was maintained 
in high glucose DMEM medium (with 2 mM L-gluta-
mine) (Sigma-Aldrich, St. Louis, MO, USA) supplement-
ed with 10% (v/v) FBS (Sigma-Aldrich, St. Louis, MO, 
USA). Both cell lines were cultured in the presence of 
1% (v/v) antibiotics/antimycotics solution (10 000 units 
of penicillin, 10 mg streptomycin, and 25 μg of ampho-
tericin B per mL) from Sigma-Aldrich (St. Louis, MO, 
USA), in a humidified incubator with 5% CO2 at 37°C. 
Subculturing was done at subconfluent densities with a 
solution of 0.25% Trypsin-EDTA solution (Life Tech-
nologies/Thermo Fisher Scientific, Waltham, MA, USA) 
for 2 minutes at 37°C.
Tetrazolium-based growth assay (MTT). The growth 
inhibitory effect of SeMet on cellular viability was eval-
uated by the MTT colorimetric method using thiazolyl 
blue tetrazolium bromide (Sigma-Aldrich, St. Louis, MO, 
USA). HT-29 cells were plated in 5 replicates in 96-well 
plates at a density of 1 × 104 cells/well in a final volume 
of 100 μl medium. After overnight incubation at 37°C, 
5% CO2, dilutions of SeMet were added in 5 replicates 
per drug concentration. Untreated cells (appropriate vol-
umes of medium added) served as controls. After 48 
h incubation, 50 µl of the MTT solution was added to 
each well and incubated for 4 h at 37°C. Medium was 
removed and the formazan product of MTT reduction 
was dissolved in 75 μl of DMSO per well. The optical 
density was measured at 550 nm. Each assay was repeat-
ed three times. Nonlinear regression graph was plotted 
between percentage of cell inhibition and log10 concen-
tration, and IC50 was determined using the GraphPad 
Prism software (Version 5.01, GraphPad Software, Inc., 
San Diego, CA, USA).
Selenomethionine treatment. SeMet (Sigma-Aldrich, 
St. Louis, MO, USA) was dissolved in medium to a 
stock concentration of 10 mM. At 48 h before the Se-
Met treatment, exponentially growing human colon can-
cer cells were seeded at a density of 1 × 105 cell/well. 
24 h before the experiment, supplemented medium was 
replaced with a serum-free medium. SeMet concentration 
range and incubation time used in the study presented 
here were based on the results of a pilot studies. Control 
cells were treated with an equivalent volume of a serum 
free medium only.
Gene expression. Total RNA was isolated from 
cell samples using the SV Total Isolation Kit (Promega 
Fitchburg, Wisconsin, USA), according to the manu-
facturer’s instructions. The RNA concentration of each 
sample was measured using the NanoDrop ND-1000 
UV-Vis Spectrophotometer (Thermo Scientific, Waltham, 
MA, USA).
The purity of extracted total RNA was determined by 
the A260/A280 ratio. cDNA was synthesized by reverse 
Figure 1. Schematic diagram showing a regulatory model of Wnt/β-catenin signalling. 
Left panel: in the absence of Wnt, constitutive activation of GSK-3β leads to β-catenin phosphorylation and subsequent proteasomal 
degradation. Right panel: in the presence of Wnt, GSK-3β is inactive (phosphorylated), β-catenin then enters the nucleus and affects 
gene transcription involved in regulation of cell cycle progression, proliferation and apoptosis. Notes: Solid and dashed arrows represent 
causal processes in the Wnt/β-catenin pathway.
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transcription of 500 ng of total RNA from each sample, 
using MMLV First-Strand Synthesis Kit (GeneDireX, 
Las Vegas City, NV, USA) according to the manufactur-
er’s protocol. The reaction was performed in a T3 Ther-
mocycler (Biometra, Göttingen, Germany). Relative gene 
expression was determined by qPCR according to the 
MIQE guidelines. The PCR primers and TaqMan probes 
for HPRT (a housekeeping gene, assay ID Hs99999909_
m1), c-Myc (assay ID Hs00153408_m1) and β-catenin 
(assay ID Hs00355049_m1) were purchased from Life 
Technologies/Thermo Fisher Scientific (Waltham, MA, 
USA). The qPCR conditions were as follows: an initial 
incubation at 50°C for 2 min, then a denaturation at 
95°C for 10 min, followed by 40 cycles of 95°C for 15 s 
and 60°C for 1 min. Temperature cycling and real-time 
fluorescence measurements were done by using Rotor-
Gene RG-3000 Corbett Research thermal cycler (Qia-
gen, Hilden, Germany). The relative quantitation of gene 
expression was done by using the 2-ΔΔCT method. Each 
qPCR experiment was done in quadruplicate (two dupli-
cates from two different reverse transcription reactions), 
and the mean CT value was used for data analysis.
Western Blotting Analysis. Whole cell lysates were 
used in Western blotting analysis. Protein content was 
determined using the Bradford assay with an Elx808 
(BioTek, Winooski, VT, USA) microtiter plate reader. 
Proteins were separated on NuPage Novex 10% Bis-
Tris polyacrylamide electrophoresis gels (Invitrogen 
Ltd, Paisley, UK). After electrophoresis, proteins were 
transferred from gels onto nitrocellulose membranes 
by using an iBlot Dry Blotting System (Invitrogen Ltd, 
Paisley, UK). The primary antibodies used for detection 
were anti-β-catenin rabbit polyclonal antibody (1:4 000), 
anti-β-catenin (phospho S33 + S37) rabbit polyclon-
al antibody (1:1000), anti-GSK-3β (phospho S9) rabbit 
polyclonal antibody (1:400), and anti-Bax rabbit poly-
clonal antibody (1:1000). Secondary antibodies were goat 
polyclonal antibodies to rabbit IgG H&L (HRP). As a 
control for protein loading, an anti-β actin rabbit poly-
clonal antibody (1:5000 dilution) was used. All antibod-
ies were obtained from Abcam (Cambridge, UK). Signals 
for protein bands were visualized by SuperSignal West 
Pico Chemiluminescent Substrate (Thermo Scientific, 
Waltham, MA, USA) according to the manufacturer’s 
protocol, and exposed to X-ray film (KODAK, Roch-
ester, MN, USA). The density of each specific band was 
measured using a computer-assisted imaging analysis sys-
tem.
Statistical Analysis. Results are presented as the 
mean values ± S.D. Statistical differences of data for two 
groups were compared by unpaired Student’s t-test. Rel-
ative expression levels from qPCR were logarithmically 
transformed prior to statistical analysis for normalization. 
For all statistical analyses, the level of significance was 
set as P<0.05. The IC50 values were calculated using the 
GraphPad Prism® 5 software (Version 5.01, GraphPad 
Software, Inc., San Diego, CA, USA).
RESULTS
The effect of SeMet administration on HT-29 and 
HaCaT cell viability
We investigated the effect of SeMet on the viability of 
HT-29 colon cancer cells and normal human keratino-
cytes HaCaT, and selected SeMet cytotoxic/antiprolifera-
tive concentrations for further experiments. The HaCaT 
cell line was used in order to get more insights as to 
whether SeMet can affect the cancerogenic HT-29 and 
non-cancerogenic (HaCaT) cell lines. The cell lines were 
exposed to SeMet for 48 h and MTT growth assay was 
performed. SeMet sensitivity values were calculated in 
terms of 50% inhibitory concentration (IC50). We ob-
served that SeMet causes a concentration-dependent 
inhibition of HT-29 growth, with an IC50 value of 283 
µM (n=3) after 48 h of incubation with this derivative of 
selenium containing amino acid (Fig. 2). In contrast, IC50 
for SeMet in HaCaT cells was 630 µM (Fig. 3).
SeMet decreases expression and protein levels of 
β-catenin
To ascertain if β-catenin is a critical factor in the an-
ti-carcinogenic effect of SeMet, we analysed the level of 
this protein by Western blotting in the HT-29 cell line 
after 48 h of incubation of these cells with SeMet at cy-
totoxic doses (IC25, IC50). The β-actin was used to nor-
malize the changes in the β-catenin signal. As shown in 
Fig. 4, incubation with SeMet at the dose of IC25 tended 
to decrease the level of β-catenin protein but this change 
was not significant. However, when the IC50 dose of Se-
Figure 2. Determination of IC50 values of SeMet on HT-29 cells. 
HT-29 cells were treated for 48 h with SeMet at concentrations 
ranging from 0 to 450 µM. MTT assay was then used to determine 
cell viability (%). IC50 values were determined after plotting the 
absorbance values vs. various drug concentrations using Graph-
Pad Prism program. The graph was then fitted with a non-linear 
regression and a sigmoidal dose-response curve to obtain the IC50 
values. Data represent the means ± S.D. (n=3).
Figure 3. Determination of IC50 values of SeMet on HaCaT cells. 
HaCaT cells were treated for 48 h with SeMet at concentrations 
ranging from 120 to 1000 µM. MTT assay was then used to de-
termine cell viability (%). IC50 values were determined after plot-
ting the absorbance values vs. various drug concentrations using 
GraphPad Prism program. The graph was then fitted with a non-
linear regression and a sigmoidal dose-response curve to obtain 
the IC50 values. Data represent the means ± S.D. (n=3).
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Met was applied, a marked decrease (approx. 2 fold vs 
control) in β-catenin protein was observed. Similar re-
sults with SeMet were obtained at mRNA level as as-
sessed by qPCR. As shown in Fig. 5, the relative gene 
expression of β-catenin significantly decreased in the Se-
Met-stimulated HT-29 cells when compared to untreated 
control cells.
SeMet ihnibits c-Myc gene expression
To determine whether SeMet can influence c-Myc 
gene expression, HT-29 cell line was incubated with 
SeMet at cytotoxic concentrations (IC25, IC50) and the 
mRNA level was investigated by qPCR. As shown in 
Fig. 6, the relative gene expression of c-Myc was signifi-
cantly decreased (approx. 12 fold for IC50 vs control) in 
the SeMet stimulated HT-29 cells when compared with 
the untreated control. These 
data suggest that SeMet can 
inhibit the growth of HT-
29 cells by inhibiting c-Myc 
gene expression.
Inhibition of β-catenin 
is due to its enhanced 
degradation and does not 
depend on GSK-3β S9 
phosphorylation status
On the basis of our pre-
vious observations we found 
that β-catenin is down-reg-
ulated by SeMet within 48 
h in colorectal cancer cell 
line which can result from 
an increased degradation 
of β-catenin. We observed 
that at cytotoxic concentra-
tions, SeMet had increased 
β-catenin phosphorylation 
at the S33 and S37 residues 
(approx. 2 folds vs. control 
at IC50; Fig. 7), and subsequently resulting in β-catenin 
proteasomal degradation. To determine the mechanism 
of β-catenin phosphorylation by SeMet, involvement of 
GSK-3β was evaluated. Treatments with SeMet signifi-
cantly increased the level of phosphorylated GSK-3β in 
HT-29 cells (approx. by 2 folds and 6 folds vs. control 
for IC25 and IC50, respectively) (Fig. 8). These results in-
dicate that SeMet caused an increase in β-catenin phos-
phorylation in the colorectal cancer cells and this effect 
appears to be independent of GSK-3β phosphorylation 
at S9.
SeMet increases pro-apoptotic Bax protein level
 The level of Bax protein with or without incubation 
with SeMet was examined in order to determine the po-
tential pro-apoptotic activity of this seleno-derivative of 
Figure 4. Effect of SeMet stimulation on β-catenin protein level. 
HT-29 cells were incubated with cytotoxic doses (IC25, IC50) of SeMet for 48 h. Left panel shows 
a representative Western blot from SeMet treated and untreated (control) HT-29 cell line. Right 
panel shows the semi-quantitative densitometry analysis of the Western blots from HT-29 incu-
bated with SeMet for 48 h. As shown, there is a significant decrease in β-catenin protein level fol-
lowing SeMet treatment with respect to the untreated control. Data are shown as the mean ± S.D. 
and are representative of three independent experiments. *P < 0.05 determined by Student’s t-test.
Figure 6. Effect of SeMet stimulation on c-Myc gene expression. 
HT-29 cells were incubated with cytotoxic doses (IC25, IC50) of Se-
Met for 48 h and mRNA was analysed by qPCR. SeMet significantly 
decreased c-Myc gene expression in HT-29 cells with respect to 
the untreated control. Experiments were performed in quadru-
plicates and quantified using HPRT as a reference gene. Data are 
shown as the mean ± S.D. and are representative of three inde-
pendent experiments. *P < 0.05 determined by Student’s t-test.
Figure 5. Effect of SeMet stimulation on β-catenin gene expres-
sion. 
HT-29 cells were incubated with cytotoxic doses (IC25, IC50) of Se-
Met for 48 h and mRNA was analysed by qPCR. SeMet significantly 
decreased β-catenin gene expression in HT-29 cells with respect 
to the untreated control. Experiments were performed in quadru-
plicates and quantified using HPRT as a reference gene. Data are 
shown as the mean ± S.D. and are representative of three inde-
pendent experiments. *P < 0.05 determined by Student’s t-test.
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methionine. As shown in Fig. 9, SeMet up-regulated pro-
apoptotic Bax protein level in HT-29 cells.
DISCUSSION
Selenium is an essential trace element in mammals and 
is usually ingested with food or dietary supplementation 
either in an organic or an inorganic form (Rayman, 2000; 
Carroll et al., 2015). Although the effect of anti-cancer 
action of selenium still remains unexplored, several 
mechanisms, such as antioxidant protection, inhibition 
of cancer cell growth, modulation of cell cycle and an 
increase in apoptosis, have been proposed to explain its 
anti-neoplastic activities (Brozmanova et al., 2010). Re-
cent studies suggest that at concentrations higher than 
nutritional requirements, selenium exerts anti-cancer po-
tential and can be used not only for cancer prevention 
but also for treatment of cancer growth (Brozmanova et 
al., 2010).
The organic selenium compounds, such as SeMet, are 
predominant forms of selenium which are considered as 
more bioavailable than its 
inorganic forms (Menter et 
al., 2000).
That is why our major 
goal was to determine the 
effect of SeMet on colon 
cancer cells and to elucidate 
if Wnt/β-catenin pathway 
could be a molecular target 
for this agent. To the best 
of our knowledge, no data 
have been previously re-
ported on the role of SeMet 
on Wnt/β-catenin pathway 
in the HT-29 colon can-
cer cells. According to the 
recent evidence, reduced 
β-catenin expression is in-
volved in induction of cell 
death by various drugs and 
nutritional factors, including 
non-steroidal anti-inflamma-
tory drugs (NSAIDs) and 
butyrate (Smith et al., 2000; 
Bordonaro et al., 2002; Ema-
nuele et al., 2004). Rao et al. 
reported that a synthetic or-
ganoselenium compound, p-
XSC, significantly suppresses 
β-catenin expression in in-
testinal polyps in the APCmin 
mouse (Rao et al., 2000). In 
another study, p-XSC also 
decreased protein levels of 
β-catenin in colon cancer 
cells (Narayanan et al., 2004).
Here, we provide direct 
evidence that selenium, in 
the form of SeMet, exerts 
anti-proliferative activity 
against the HT-29 cell line. 
The mean IC50 value for 
HT-29 cells was 283 µM at 
exposure durations of 48 h. 
Similar results were reported 
by Redman et al., who found 
that SeMet inhibits growth 
of human tumour cell lines 
at concentrations within the micromolar (µM) range and 
in a dose-dependent manner (Redman et al., 1998). They 
also demonstrated that the sensitivities of tumour and 
normal cells to SeMet were highly diverse. This is con-
sistent with our findings. We observed that the cytotox-
ic dose (IC50) of SeMet for normal human keratinocyte 
(HaCaT) cell line was approx. 2 folds higher than for the 
tumour HT-29 cells (IC50 = 630 µM).
Furthermore, we found that administration of SeMet 
at effective anti-proliferative doses had significantly de-
creased β-catenin level in the HT-29 cell lysates. Moreo-
ver, this effect was accompanied by down-regulation of 
c-Myc mRNA. Similarly, Zeng et al. reported that submi-
cromolar concentrations of methylselenol, generated by 
incubating methionase with SeMet, inhibited c-Myc ex-
pression in the HT1080 fibrosarcoma cells (Zeng et al., 
2009). In turn, studies conducted by Zhang et al. revealed 
that c-Myc mRNA and protein levels were significantly 
decreased upon methylseleninic acid (MSA) treatment in 
human oesophageal squamous cell carcinoma cell lines 
Figure 7. Effect of SeMet stimulation on phospho-β-catenin protein level. 
HT-29 cells were incubated with cytotoxic doses (IC25, IC50) of SeMet for 48 h. Left panel shows 
a representative Western blot from SeMet treated and untreated (control) HT-29 cell line. Right 
panel shows the semi-quantitative densitometry analysis of the Western blots from HT-29 incu-
bated with SeMet for 48 h. As shown, there is a significant increase in phopsho-β-catenin protein 
level following SeMet treatment with respect to the untreated controls. Data are shown as the 
mean ± S.D. and are representative of three independent experiments. *P < 0.05 determined by 
Student’s t-test.
Figure 8. Effect of SeMet stimulation on phospho-GSK-3β protein level. 
HT-29 cells were incubated with cytotoxic doses (IC25, IC50) of SeMet for 48 h. Left panel shows 
a representative Western blot from SeMet treated and untreated (control) HT-29 cell line. Right 
panel shows the semi-quantitive densitometry analysis of the Western blots from HT-29 incubated 
with SeMet for 48 h. As shown, there is a significant increase in phospho-GSK-3β protein level fol-
lowing SeMet treatment with respect to the untreated controls. Data are shown as the mean ± S.D. 
and are representative of three independent experiments. *P < 0.05 determined by Student’s t-test.
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EC9706 and KYse150 (Zhang et al., 2010). Likewise, 
MSA reduced β-catenin protein levels, indicating that ap-
optosis and growth inhibition induced by MSA could be 
modulated through β-catenin-TCF/LEF pathway (Zhang 
et al., 2010). This is compatible with our observation. 
SeMet-induced β-catenin down-regulation in the HT-29 
colon cancer cells was followed by down-regulation of 
c-Myc, reflecting a launch of a causal relationship be-
tween β-catenin and c-Myc, which finally leads to inhibi-
tion of cancer cell growth.
To determine whether the decrease in β-catenin 
protein level resulted from an increase in its degrada-
tion, the phosphorylation of β-catenin and GSK-3β 
was evaluated in the presence and absences of SeMet. 
The β-catenin protein level is normally kept low by its 
phosphorylation at S33 and S37, mediated by GSK-3β, 
which results in the β-catenin targeting for proteasomal 
degradation. The presence of Wnt blocks phosphoryla-
tion, thereby allowing β-catenin to accumulate and trans-
locate into the nucleus, where it co-operates with sev-
eral transcription factors (Gao et al., 2014). Our data 
indicate that SeMet caused 
an increase in β-catenin 
phosphorylation (at S33 and 
S37 residues, as commonly 
recognized), thus, showing 
that cytotoxic doses of Se-
Met can promote β-catenin 
degradation. Moreover, we 
found a significant reduction 
in β-catenin mRNA after 
SeMet treatment. However, 
mechanisms underlying this 
effect remain unclear to us. 
Bandapalli et al. provided 
several lines of evidence that 
β-catenin can induce tran-
scription from its own pro-
moter, thereby up-regulating 
its expression. Thus, they 
considered β-catenin as a 
positive feedback activator 
for Wnt/β-catenin signal-
ling (Bandapalli et al., 2009). 
Taking this notion into consideration, it is possible that 
SeMet reduces β-catenin gene expression and this effect 
is responsible for β-catenin-protein down-regulation ob-
served in our study. On the other hand, according to 
Ebert et al., regulation of β-catenin transcription through 
β-catenin itself seems unlikely, since the β-catenin pro-
moter does not contain a TCF-responsive element. The 
above, however, does not change the fact that β-catenin 
transcription might be regulated by other transcription 
factors which are triggered by the β-catenin-TCF/LEF 
complex (Ebert et al., 2002).
It has been clearly established that phosphorylation at 
S9 correlates with inhibition of the GSK-3β activity (Mc-
Cubrey et al., 2014). However, involvement of GSK-3β 
phosphorylation in Wnt signalling remains unexplored 
and has not been carefully studied thus far (Gao et al., 
2014). Our present findings provide an alternative to 
the widely accepted molecular mechanism for regulation 
of cytoplasmic β-catenin by activation of β-catenin deg-
radation pathway. Interestingly, we found that β-catenin 
protein down-regulation was accompanied by simultane-
ous phosphorylation of GSK-3β at S9 upon SeMet treat-
ment. This remains at odds with the observation of Safio 
et al. who reported that administration of methyl selenic 
acid (MSeA) had no significant effect on the level of to-
tal GSK-3β (in HT-29 or HCT-8) and failed to alter the 
level of phosphorylated GSK-3β in HCT-8. In contrast, 
GSK-3β phosphorylated at S9 was significantly decreased 
in HT-29 cells (Saifo et al., 2010). On the other hand, Liu 
et al. have found that the Siah-1 protein, a p53-inducible 
mediator of cell cycle arrest, tumour suppression, and 
programmed cell death, interacts with the carboxyl ter-
minus of APC and promotes degradation of β-catenin in 
mammalian cells that is independent of GSK3β-mediated 
phosphorylation (Liu et al., 2001). In turn, Dihlmann et al. 
demonstrated that NSAIDs cause an increase in the level 
of phosphorylated form of β-catenin (S33 + S37 + T41) in 
colorectal and colon cancer cell cultures, and this altera-
tion was mediated by simultaneous increase in GSK-3β 
phosphorylation. However, no changes in GSK-3β phos-
phorylation level were observed in normal embryonic kid-
ney cells (HEK 293) (Dihlmann et al., 2003). Their results, 
demonstrating that aspirin can elevate GSK-3β phospho-
rylation at S9 in colon cancer cells, suggest that NSAID 
might stabilize selected S/T-phosphorylation by inhibiting 
a phosphatase known to revert proteins into their unphos-
Figure 9. Effect of SeMet stimulation on Bax protein level. 
HT-29 cells were treated with cytotoxic doses (IC25, IC50) of SeMet for 48 h. Left panel shows a rep-
resentative Western blot from SeMet treated and untreated (control) HT-29 cell line. Right panel 
shows the semi-quantitative densitometry analysis of the Western blots from HT-29 incubated 
with SeMet for 48 h. As shown, there is a significant increase in Bax protein level following SeMet 
treatment with respect to the untreated controls. Data are shown as the mean ± S.D. and are rep-
resentative of two independent experiments. *P < 0.05 determined by Student’s t-test.
Figure 10. The effect of SeMet on the Wnt/β-catenin pathway. 
We hypothesize that SeMet promotes degradation of β-catenin 
and suppresses its translocation into the nucleus, thereby inhibit-
ing c-Myc gene expression. SeMet also possesses a GSK-3β-inhib-
itory and pro-apoptotic activity as reflected by an increased level 
of the Bax protein. Notes: Solid arrows: degradation of β-catenin/
Bax activation; dashed arrow: possible Bax activation via S9 phos-
phorylated GSK-3β; blunt-ended arrow: inhibition of GSK-3β activi-
ty/inhibition of c-Myc gene expression.
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phorylated forms (Dihlmann et al., 2003). Thus, it cannot 
be excluded that in our studies SeMet triggered the Wnt/
β-catenin in a similar manner as previously described, and 
SeMet might indirectly inactivate specific phosphatases 
targeting β-catenin and GSK-3β. However, the proposed 
mechanism remains to be elucidated in further studies.
The GSK-3β plays pivotal roles in cancer development 
which remain complex and are still controversial (Mc-
Cubrey et al., 2014). GSK-3β is overexpressed in many 
tumour types including: colon, liver, ovarian and pancre-
atic tumours (McCubrey et al., 2014). Besides promoting 
β-catenin proteasome degradation, it can phosphorylate 
and stabilize Wnt-coreceptor LRP5/6 which fosters β-cat-
enin signalling. Consecutively, inhibitors of this kinase 
could arrest β-catenin-mediated gene expression and may 
eventually be used in treatment of certain cancers (Mc-
Cubrey et al., 2014). Zhou et al. demonstrated that sup-
pression of GSK-3β inhibited pancreatic cancer growth 
and angiogenesis (Zhou et al., 2012). Similarly, treatment 
of leukaemia cell lines with a GSK-3β inhibitor resulted 
in GSK-3β S9 phosphorylation, β-catenin stabilization, 
cyclin B down-regulation, inhibition of cell growth, cell 
cycle arrest at G2/M, and promotion of apoptotic cell 
death (Mirlashari et al., 2012). Interestingly, according to 
Tan et al., GSK-3β inhibition promotes p53-dependent 
apoptosis through a Bax-mediated mitochondrial pathway. 
They noticed that a modulation of GSK-3β by inhibitors 
(LY2119301 and lithium) was able to convert the p53 re-
sponse from growth arrest to apoptosis. In their opinion, 
increased S9 phosphorylation of GSK-3β by LY2119301 
or lithium could displace Bax, promoting its activation 
and cell death (Tan et al., 2005). Therefore, in agreement 
with these studies, we provided evidence that SeMet was 
able to up-regulate pro-apoptotic Bax, suggesting that this 
effect can be mediated by an increased S9 phosphoryla-
tion of GSK-3β.
In summary, we hypothesize that GSK-3β phosphoryla-
tion at S9 may not be the limiting component for Wnt-sig-
nalling in colon cancer cells. Even more, GSK-3β inhibi-
tion, resulting from SeMet treatment, may function as a 
tumour suppressor and can promote apoptotic cell death.
CONCLUSIONS
Our studies revealed that SeMet inhibits growth of the 
HT-29 colon cancer cell line by targeting the Wnt/β-caten-
in pathway and this is due, at least in part, to an increase 
in the Bax-mediated apoptosis. However, the latter requires 
confirmation in further studies conducted under in vitro and 
in vivo conditions. We conclude that β-catenin and GSK-3β 
appear to act as key targets for SeMet in colorectal cancer 
cells, leading to down-regulation of c-Myc gene expression. 
Moreover, SeMet-induced β-catenin degradation seems to 
occur independently of the status of GSK-3β catalytic activ-
ity and S9 phosphorylation (Fig. 10).
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